Recently, treating MAGL as a potential therapeutic target for depression, Zhuoer Zhi et al. were the first to develop an aryl formyl piperidine derivative inhibitor that was found to significantly improve depressive-like behavior induced by reserpine [32]. The gene discussed is MGLL; the disease is depressive disorder.